Recordati

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 11:45:00 2026-01-16 am EST			5-day change	1st Jan Change
47.98 ^EUR	-0.58%		-3.23%	-1.15%

Jan. 14	Recordati Industria Chimica e Farmaceutica S.p.A. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM
Jan. 12	Recordati Acquires 74,165 Own Ordinary Shares	AN

Felice La Corte buys 4,000 Recordati shares

Published on 12/10/2025 at 01:57 pm EST

Alliance News - Translated by Marketscreener - See original

Recordati

-0.58%

(Alliance News) - On Wednesday, Recordati Spa announced an internal dealing transaction carried out by director Luigi Felice La Corte.

La Corte purchased 4,000 ordinary shares in the company at an average price of EUR48.5833 per share, for a total value of EUR194,333.20.

Recordati shares closed Wednesday's trading down 1.8% at EUR47.26 per share.

By Michele Cirulli, Alliance News Reporter

Comments and questions to redazione@alliancenews.com

Latest news about Recordati

Jan. 14	Recordati Industria Chimica e Farmaceutica S.p.A. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM
Jan. 12	Recordati Acquires 74,165 Own Ordinary Shares	AN
Jan. 07	STRM.BIO, Inc. announces tranche update	CI
Jan. 05	Recordati Buys Back 52,000 Own Shares for Over EUR2 Million	AN
Dec. 31	US FDA declines to approve Corcept's drug for rare hormonal disorder	RE
Dec. 23	Recordati Acquires 13,050 Own Shares for Approximately EUR570,000	AN
Dec. 18	Mixed European Markets, Central Banks in the Spotlight	AN
Dec. 17	Mixed European Markets Ahead of ECB Decision, Mib Turns Bullish	AN
Dec. 17	Mixed results in Europe; Saipem leads the gains	AN
Dec. 17	Mib opens higher; strength in banking stocks	AN
Dec. 16	Recordati launches new buyback program of up to EUR55 million	AN
Dec. 10	Felice La Corte buys 4,000 Recordati shares	AN
Dec. 08	Mib down; MPS at the top of the list	AN
Dec. 08	Recordati CEO Acquires 2,000 Ordinary Shares	AN
Nov. 17	Futures show stability; macro data expected	AN
Nov. 14	Mib Drops Below 44,000; Azimut Bucks the Trend	AN
Nov. 13	Mib at 45,000 points; Buzzi and Azimut down sharply	AN
Nov. 13	European Markets Set to Open Higher After End of U.S. Shutdown	AN
Nov. 12	European Markets Climb, Mib Leads with Mediobanca	AN
Nov. 12	Recordati Industria Chimica e Farmaceutica S.p.A., Nine Months 2025 Earnings Call, Nov 12, 2025
Nov. 12	Mediobanca Leads Gains; Strong Performance for De' Longhi on the Mid-Cap	AN
Nov. 12	European stocks rally; Fed and US optimism as markets reopen	AN
Nov. 12	Recordati says 2025 profit to be hit by weak economy, currency impact	RE
Nov. 12	Bullish markets; Mib starts again from 43,400	AN
Nov. 12	Italy - Factors to watch on November 12	RE

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (64.4%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (35.6%). Net sales are distributed geographically as follows: Italy (14.3%), Europe (56.1%), America (20.4%), Asia and Oceania (6.7%) and Africa (2.5%).

Employees

4,539

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company